|
|
Article: "Pipeline Insight: Neuropathic Pain - Pipeline Drugs Fail to Nail Neuropathic Pain" by Datamonitor July 2005.
- Article from:
- M2 Presswire
- Article date:
- August 16, 2005
CopyrightCOPYRIGHT 2005 Normans Media Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
M2 PRESSWIRE-16 August 2005-MarketResearch.com: "Pipeline Insight: Neuropathic Pain - Pipeline Drugs Fail to Nail Neuropathic Pain" by Datamonitor July 2005(C)1994-2005 M2 COMMUNICATIONS LTD
RDATE:15082005
The neuropathic pain market has traditionally been a poorly defined area, with widely varying drug classes prescribed. With many drugs now in clinical trials for key neuropathic pain sub-types, pharma companies with powerful marketing arms are expected to bring attention to this potentially lucrative market and its considerable unmet needs.
Scope
~ Overview of patient potential, segmentation by indication and unmet needs in ...